Description
On August 5, 2022, the Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu) for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH‑) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.
References:
- FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer
- FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors
- FDA approval makes Enhertu an option for multiple tumour indications
- AstraZeneca Pharma India to launch cancer drug Enhertu in January
